<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00602797</url>
  </required_header>
  <id_info>
    <org_study_id>339-07</org_study_id>
    <secondary_id>NCI-2009-01584</secondary_id>
    <secondary_id>339-07</secondary_id>
    <secondary_id>P30CA036727</secondary_id>
    <nct_id>NCT00602797</nct_id>
  </id_info>
  <brief_title>Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase II Study of Weekly Vinorelbine and Paclitaxel in Elderly Patients With Advanced Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the side effects and how well vinorelbine tartrate and
      paclitaxel works in treating older patients with advanced non-small cell lung cancer. Drugs
      used in chemotherapy, such as vinorelbine tartrate and paclitaxel, work in different ways to
      stop the growth of tumor cells, either by killing the cells or by stopping them from
      dividing. Giving combination chemotherapy may kill more tumor cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      I. To assess the safety and efficacy of a combination of vinorelbine and paclitaxel
      administered weekly to elderly patients with advanced non-small cell lung cancer.

      II. To assess the response rate of a combination of vinorelbine and paclitaxel administered
      weekly to elderly patients with advanced non-small cell lung cancer.

      III. To assess the quality of life of elderly patients with advanced non-small cell lung
      cancer during administration of weekly paclitaxel and vinorelbine.

      OUTLINE:

      Patients receive vinorelbine tartrate intravenously (IV) over 6-10 minutes and paclitaxel IV
      over 1 hour once weekly for 6 weeks. Treatment repeats every 8 weeks for up to 2 courses in
      the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 3 months for 2 years and
      then every 6 months for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2007</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Time from first therapy until first documentation of clinical progression, relapse or death assessed up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Kaplan-Meier method will be used to estimate time to event distributions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-hematological toxicity</measure>
    <time_frame>Up to week 17</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Toxicity will be assessed at the 0.05 two-sided level of significance. The Common Terminology Criteria for Adverse Events Version 3.0 will be used to grade the severity of adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The measurement of effect will be based on the Response Evaluation Criteria In Solid Tumors criteria.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">29</enrollment>
  <condition>Recurrent Non-small Cell Lung Cancer</condition>
  <condition>Stage IIIB Non-small Cell Lung Cancer</condition>
  <condition>Stage IV Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (vinorelbine tartrate, paclitaxel)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive vinorelbine tartrate IV over 6-10 minutes and paclitaxel IV over 1 hour once weekly for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine tartrate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (vinorelbine tartrate, paclitaxel)</arm_group_label>
    <other_name>Eunades</other_name>
    <other_name>navelbine ditartrate</other_name>
    <other_name>NVB</other_name>
    <other_name>VNB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (vinorelbine tartrate, paclitaxel)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>TAX</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (vinorelbine tartrate, paclitaxel)</arm_group_label>
    <other_name>quality of life assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (vinorelbine tartrate, paclitaxel)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically proven non-small cell lung cancer with evidence of distant
             metastases/malignant pleural effusion

          -  Measurable disease on imaging studies in 2 dimensions

          -  No previous therapy with either paclitaxel or vinorelbine, or any chemotherapy for
             the past five years

          -  Patients who have had a previous resection for their lung cancer and present with
             recurrent disease will be eligible

          -  Patients with other prior malignancies will be included, provided they have been
             disease-free for at least five years

          -  Patients with adequately treated basal cell or squamous cell carcinoma of the skin,
             adequately treated carcinoma in-situ of the cervix and hormone sensitive prostate
             cancer will be eligible

          -  Karnofsky score &gt;= 70 (Eastern Cooperative Oncology Group [ECOG] 0-2)

          -  White blood cell (WBC) count &gt;= 3,500/mm^3, OR

          -  Absolute neutrophil count (ANC) &gt;= 1,500/ul

          -  Platelet count &gt;= 100,000/mm^3

          -  Serum creatinine less than 1.5 times the upper limits of normal

          -  Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than
             1.5 times the upper limits of normal

          -  Serum alkaline phosphatase less than 2.5 times the upper limits of normal

          -  No active serious infections or other condition precluding chemotherapy

          -  Non-pregnant and non-nursing

          -  Men and women of reproductive potential may not participate unless they have agreed
             to use an effective contraceptive method while on the study

          -  Able to give informed consent

          -  Able to return for treatment and follow-up as specified in the protocol

        Exclusion Criteria:

          -  Known hypersensitivity to any component of vinorelbine or paclitaxel or other
             required drugs in the study

          -  Any comorbidity or condition which, in the opinion of the investigator, may interfere
             with the assessments and procedures of this protocol

          -  Inability to fulfill the requirements of the protocol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Apar Ganti</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint Francis Medical Center</name>
      <address>
        <city>Grand Island</city>
        <state>Nebraska</state>
        <zip>68803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehmet S. Copur</last_name>
      <phone>308-398-6518</phone>
      <email>mcopur@sfmc-gi.org</email>
    </contact>
    <investigator>
      <last_name>Mehmet S. Copur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Plains Regional Medical Center</name>
      <address>
        <city>North Platte</city>
        <state>Nebraska</state>
        <zip>69103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irfan A. Vaziri</last_name>
      <phone>308-696-7864</phone>
      <email>vazirii@mail.gprmc.com</email>
    </contact>
    <investigator>
      <last_name>Irfan A. Vaziri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Omaha Veterans Administration Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Apar K. Ganti</last_name>
      <phone>402-995-4171</phone>
      <email>aganti@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Apar K. Ganti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Apar K. Ganti</last_name>
      <phone>402-559-6210</phone>
      <email>aganti@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Apar K. Ganti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Avera McKennan Hospital and University Health Center</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Addison R. Tolentino</last_name>
      <phone>800-657-4377</phone>
      <email>Jan.Healy@avera.org</email>
    </contact>
    <investigator>
      <last_name>Addison R. Tolentino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 1, 2014</lastchanged_date>
  <firstreceived_date>January 15, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Apar Kishor Ganti, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
